Related Experiment Video
Updated: Aug 7, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Pharmacoeconomics applied to chronic hepatitis C
Fernando Franciosi Tatsch1, Hoel Sette, Denizar Vianna
1Gerente médico de Divisāo de Virologia/TX Roche, Brazil. fernando.tatsch@roche.com
Summary
Increased life expectancy is linked to medical advancements, necessitating economic analysis. Pharmacoeconomics helps evaluate costs for diseases like Hepatitis C, showing peginterferon alfa-2a is cost-effective for HCV treatment.
Area of Science:
- Health Economics
- Pharmacoeconomics
- Hepatology
Background:
- Global life expectancy has risen due to improved education, socio-economic factors, and medical progress.
- Medical technology advancements require significant investment, making health economics crucial.
- Hepatitis C is a prevalent, chronic global disease requiring effective treatment strategies.
Purpose of the Study:
- To explain the rationale behind health economic analysis in medicine.
- To review a pharmacoeconomic model for Hepatitis C treatment.
- To assess the cost-effectiveness of peginterferon alfa-2a for Hepatitis C Virus (HCV) infection.
Main Methods:
- Review of health economic analysis principles.
- Analysis of a specific pharmacoeconomic model for Hepatitis C.
- Evaluation of treatment costs and patient outcomes.
Main Results:
- Peginterferon alfa-2a (40KD) was found to be cost-effective.
- The study focused on a non-Brazilian scenario.
- Health economic analysis provides a framework for evaluating medical interventions.
Conclusions:
- Pharmacoeconomic evaluations are essential for managing healthcare costs and patient needs.
- Peginterferon alfa-2a represents a cost-effective treatment option for Hepatitis C.
- Continued development in health economics is vital for sustainable healthcare advancements.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...